| dc.contributor.author | Ball, Susan | |
| dc.contributor.author | Vickery, J | |
| dc.contributor.author | Hobart, J | |
| dc.contributor.author | Wright, D | |
| dc.contributor.author | Green, C | |
| dc.contributor.author | Shearer, J | |
| dc.contributor.author | Nunn, A | |
| dc.contributor.author | Gomez Cano, M | |
| dc.contributor.author | MacManus, D | |
| dc.contributor.author | Miller, D | |
| dc.contributor.author | Mallik, S | |
| dc.contributor.author | Zajicek, J | |
| dc.date.accessioned | 2015-04-20T09:26:26Z | |
| dc.date.issued | 2015-02 | |
| dc.description.abstract | The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial aimed to determine whether or not oral Δ(9)-tetrahydrocannabinol (Δ(9)-THC) slowed the course of progressive multiple sclerosis (MS); evaluate safety of cannabinoid administration; and, improve methods for testing treatments in progressive MS. | en_GB |
| dc.description.sponsorship | The National Institute for Health Research Health Technology Assessment programme | en_GB |
| dc.description.sponsorship | Medical Research Council Efficacy and Mechanism Evaluation programme | en_GB |
| dc.description.sponsorship | Multiple Sclerosis Society | en_GB |
| dc.description.sponsorship | Multiple Sclerosis Trust | en_GB |
| dc.identifier.citation | Health Technology Assessment, 2015, Vol. 19, Issue 12, pp. 1 - 188 | en_GB |
| dc.identifier.doi | 10.3310/hta19120 | |
| dc.identifier.uri | http://hdl.handle.net/10871/16885 | |
| dc.language.iso | en | en_GB |
| dc.publisher | NIHR Health Technology Assessment Programme | en_GB |
| dc.relation.url | http://www.ncbi.nlm.nih.gov/pubmed/25676540 | en_GB |
| dc.rights | © Queen’s Printer and Controller of HMSO 2015. This work was produced by Ball et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. | en_GB |
| dc.title | The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. | en_GB |
| dc.type | Article | en_GB |
| dc.date.available | 2015-04-20T09:26:26Z | |
| dc.identifier.issn | 1366-5278 | |
| exeter.place-of-publication | England | |
| dc.description | This is a freely-available open access publication. Please cite the published version which is available via the DOI link in this record. | en_GB |
| dc.identifier.journal | Health Technology Assessment | en_GB |
